New therapy on the horizon for ALK-positive non-small cell lung cancer

A new compound that targets anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer is well-tolerated by patients and is already showing early signs of activity, including in patients who no longer respond to crizotinib, the only FDA approved ALK inhibitor. Results of this study were presented by a researcher from Fox Chase Cancer Center during the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO), 1-5 June, Chicago. Read the ESMO news article here.